Nontricyclic antidepressants - Predictors of nonadherence

摘要: Second-generation antipsychotics (SGAs) have generally replaced classic neuroleptics in managing bipolar disorder because of their property inducing extrapyramidal symptoms (EPS) less frequently than conventional agents. However, EPS and tardive dyskinesia both remain a concern especially patients who may be at greater risk developing these unwanted events. Hence, the aim this study was to identify definite rank order potential among such All original research articles published English on use SGAs for treatment were identified through comprehensive Medline search. Only double-blind, randomized, placebo- and/or active comparator-controlled studies evaluating effectiveness atypical included article. Available literature data seem suggest that occur significantly proportion aripiprazole-treated placebo-treated patients. The relevant bias characterizing most quetiapine trials makes finding incidence does not differ statistically between medicated placebo groups doubtful. Among SGAs, risperidone seems associated with highest doses lower 6 mg/d. Conversely, olanzapine appear quite reassuring. Although it has been reported there are no significant differences ziprasidone- rates EPS, information requires further confirmation. Thus, as regards should considered first-choice medication clinicians take into consideration relatively high metabolic complications well other SGAs.